COVID-19: Immunology and treatment options

S Felsenstein, JA Herbert, PS McNamara… - Clinical …, 2020 - Elsevier
The novel coronavirus SARS-CoV2 causes COVID-19, a pandemic threatening millions. As
protective immunity does not exist in humans and the virus is capable of escaping innate …

Current status of potential therapeutic candidates for the COVID-19 crisis

J Zhang, B Xie, K Hashimoto - Brain, behavior, and immunity, 2020 - Elsevier
Abstract As of April 15, 2020, the ongoing coronavirus disease 2019 (COVID-2019)
pandemic has swept through 213 countries and infected more than 1,870,000 individuals …

[HTML][HTML] SARS-CoV-2 inflammatory syndrome. Clinical features and rationale for immunological treatment

M Prete, E Favoino, G Catacchio, V Racanelli… - International Journal of …, 2020 - mdpi.com
The current pandemic coronavirus, SARS-CoV-2, is a global health emergency because of
its highly contagious nature, the great number of patients requiring intensive care therapy …

VEXAS syndrome in a patient with previous spondyloarthritis with a favourable response to intravenous immunoglobulin and anti-IL17 therapy

M Magnol, L Couvaras, Y Degboé, E Delabesse… - …, 2021 - academic.oup.com
DEAR EDITOR, Beck et al.[1] recently identified a genetic disorder that connects seemingly
unrelated adult-onset inflammatory syndromes as VEXAS syndrome. We report a case of …

[HTML][HTML] Intravenous immunoglobulins as immunomodulators in autoimmune diseases and reproductive medicine

T Velikova, M Sekulovski, S Bogdanova, G Vasilev… - Antibodies, 2023 - mdpi.com
Intravenous administration of immunoglobulins has been routinely used for more than 60
years in clinical practice, developed initially as replacement therapy in immunodeficiency …

Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from systematic literature review and from real life experience

E Agostini, G De Luca, C Bruni, F Bartoli, L Tofani… - Autoimmunity …, 2021 - Elsevier
Introduction Intravenous immunoglobulins (IVIG) are a new therapeutic approach in
systemic sclerosis SSc. An immunomodulatory and antifibrotic activity has been postulated …

[HTML][HTML] Current and innovated managements for autoimmune bullous skin disorders: An overview

KY Chu, HS Yu, S Yu - Journal of Clinical Medicine, 2022 - mdpi.com
Autoimmune bullous skin disorders are a group of disorders characterized by the formation
of numerous blisters and erosions on the skin and/or the mucosal membrane, arising from …

Biomaterials-based opportunities to engineer the pulmonary host immune response in COVID-19

BM Jarai, Z Stillman, K Bomb, AM Kloxin… - ACS biomaterials …, 2020 - ACS Publications
The COVID-19 pandemic caused by the global spread of the SARS-CoV-2 virus has led to a
staggering number of deaths worldwide and significantly increased burden on healthcare as …

Scleromyxedema

JHO Hoffmann, AH Enk - JDDG: Journal der Deutschen …, 2020 - Wiley Online Library
Scleromyxedema is a rare, cutaneous deposition disorder from the group of mucinoses,
which can affect multiple organs and is virtually always associated with a monoclonal …

Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis

N Farina, C Campochiaro, A Lescoat… - Expert Review of …, 2023 - Taylor & Francis
ABSTRACT Introduction Systemic sclerosis (SSc) is a systemic disease encompassing
autoimmunity, vasculopathy, and fibrosis. SSc is still burdened by high mortality and …